Kevin is a co-founder and Partner at Medicxi. Prior to Medicxi, Kevin was a Partner at Index Ventures for 13 years, having joined the firm in 2003. Kevin originated Index’s first asset-centric investment in PanGenetics (acquired by Abbott) and led Medicxi’s investment in Impact Biomedicines (acquired by Celgene). Kevin currently serves on the boards of a number of portfolio companies, including Levicept, Superx, Capella Bioscience, UltraHuman, Apcintex and Breakpoint Therapeutics.
Prior to joining Index, Kevin was with Cambridge Antibody Technology (CAT). During his tenure at CAT, he was appointed Head of Research in 1994 and then Research Director and Chief Technology Officer in 1997. Kevin led the development of CAT's platform technologies and oversaw their application in the discovery of a number of human antibodies - two of which are now marketed worldwide: Humira (by Abbott Pharmaceuticals) and Benlysta (by GlaxoSmithKline). Kevin was part of the management team that floated CAT on the London Stock Exchange (subsequently acquired by AstraZeneca).
Kevin received a BSc in Molecular Biology from Edinburgh University and a PhD in Pathology from Cambridge University. He also acts as chairman of Crescendo Biologics and sits on the strategic advisory committee of Hilleman Laboratories.